文献速递心血管PET

骨闪烁显像检测Phe64Leu突变相关转甲状腺素蛋白心脏淀粉样变性的低敏感性

Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2019-12-18

本研究在7个意大利三级中心回顾性分析55例Phe64Leu转甲状腺素蛋白突变患者,其中26例有明确心脏受累,19例接受99mTc-DPD或99mTc-HMDP骨闪烁显像。17例(89.5%)心肌摄取低或无,仅2例(10.5%)呈高分级摄取,骨闪烁显像检测转甲状腺素蛋白心脏淀粉样变性的敏感度为10.5%、准确率为37%。

要点

  • Phe64Leu突变相关心脏淀粉样变性患者中,骨闪烁显像心肌摄取多为低或无,敏感度仅10.5%。
  • 心肌摄取低或无与高分级摄取两组在年龄、性别及心电图、超声心动图表现上相似。
  • 骨闪烁显像对转甲状腺素蛋白心脏淀粉样变性的诊断准确性可能因突变类型而异。

关键影像表现/征象

  • 26例明确心脏受累患者中,19例接受骨闪烁显像,其中17例(89.5%)心肌骨示踪剂摄取低或无。
  • 仅2例(10.5%)显示高分级心肌摄取。
  • 心肌摄取低或无组与高分级摄取组在年龄、性别、心电图和超声心动图表现上相似。

诊断标准与关键数值

  • 骨闪烁显像检测转甲状腺素蛋白心脏淀粉样变性的敏感度为10.5%,准确率为37%。
  • 心脏受累定义:舒张末期室间隔厚度≥12 mm,且无其他左心室肥厚原因(如动脉高血压或瓣膜病)。
  • 视觉评分采用Perugini法。

临床应用与阅片要点

  • 在Phe64Leu突变患者中,骨闪烁显像心肌摄取低或无不能排除心脏淀粉样变性。
  • 报告骨闪烁显像时需结合突变类型解读,Perugini评分低或无时仍需考虑心脏受累可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to assess the diagnostic accuracy of bone scintigraphy in a large multicenter cohort of patients with cardiac amyloidotic involvement and Phe64Leu transthyretin (TTR) mutation.

BACKGROUND: Diagnostic accuracy of bone scintigraphy for transthyretin-related cardiac amyloidosis (TTR-CA) is considered extremely high, enabling this technique to be the noninvasive diagnostic standard for TTR-CA. Nevertheless, this approach has not been systematically validated across the entire spectrum of TTR mutations.

METHODS: A total of 55 patients with Phe64Leu TTR mutation were retrospectively analyzed and evaluated between 1993 and 2018 at 7 specialized Italian tertiary centers. Cardiac involvement was defined as presence of an end-diastolic interventricular septum thickness ≥12 mm, without other possible causes of left ventricular hypertrophy (i.e., arterial hypertension or valvulopathies). A technetium-99m (99mTc)-diphosphonate (DPD) or 99mTc-hydroxyl-methylene-diphosphonate (HMDP) bone scintigraphy was reviewed, and visual scoring was evaluated according to Perugini's method.

RESULTS: Among 26 patients with definite cardiac involvement, 19 underwent 99mTc-DPD or 99mTc-HMDP bone scintigraphy. Of them, 17 (89.5%) patients had low or absent myocardial bone tracer uptake, whereas only 2 (10.5%) showed high-grade myocardial uptake. The sensitivity and the accuracy of bone scintigraphy in detecting TTR-CA were 10.5% and 37%, respectively. Patients with cardiac involvement and low or absent bone tracer uptake were similar to those with high-grade myocardial uptake in terms of age, sex, and electrocardiographic and echocardiographic findings.

CONCLUSIONS: The sensitivity of bone scintigraphy (DPD and HMDP) in detecting TTR-CA is extremely low in patients with Phe64Leu TTR mutation, suggesting the need to assess diagnostic accuracy of bone scintigraphy to identify cardiac involvement across a wider spectrum of TTR mutations.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Musumeci MB, Cappelli F, Russo D, et al. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2019. PMID: 31864976. doi:10.1016/j.jcmg.2019.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。